Normalising the metabolic hostility of the TME (via buffering agents, GLUT1 inhibition, lactate/MCT targeting, or systemic metabolic modulators) may reopen access to tumour sites but may be insufficient alone if infiltrating T cells are already exhausted or epigenetically fixed. This evidence concerns the gene SLC2A1 and neoplasm.